scholarly journals Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARγ signaling pathway

2009 ◽  
Vol 30 (9) ◽  
pp. 1316-1322 ◽  
Author(s):  
Liang-qi Cao ◽  
Xiao-li Wang ◽  
Qian Wang ◽  
Ping Xue ◽  
Xing-yuan Jiao ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Antitumor Activity ◽  
Signaling Pathway ◽  
Cell Lines ◽  
Carcinoma Cell ◽  
Carcinoma Cell Lines ◽  
Hepatocellular Carcinoma Cell

scholarly journals NT157 Inhibits HCC Migration via Downregulating the STAT3/Jab1 Signaling Pathway

2021 ◽  
Vol 20 ◽  
pp. 153303382110279
Author(s):  
SiZhe Yu ◽  
Yu Wang ◽  
KeJia Lv ◽  
Jia Hou ◽  
WenYuan Li ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cell Lines ◽  
Lung Metastasis ◽  
Carcinoma Cell ◽  
Binding Protein ◽  
Signal Transducer ◽  
Activation Domain ◽  
Carcinoma Cell Lines ◽  
Hepatocellular Carcinoma Cell ◽  
Transcription 3

Purpose: The high fatality-to-case ratio of hepatocellular carcinoma is directly related to metastasis. The signal transducer and activator of transcription-3 is a key mediator of the cytokine and growth factor signaling pathways and drives the transcription of genes responsible for cancer-associated phenotypes. However, so far, no specific inhibitor for signal transducer and activator of transcription-3 has been used in clinical practice. Therefore, targeting the signal transducer and activator of transcription-3 for cancer therapy is highly desired to improve outcomes in patients with hepatocellular carcinoma. Experimental Design: Using the small-molecule inhibitor NT157, the effect of signal transducer and activator of transcription-3 inhibition on cell migration was tested in hepatocellular carcinoma cell lines and a lung metastasis model of the disease. Results: NT157 significantly inhibited the migration of hepatocellular carcinoma cell lines in vitro and lung metastasis of hepatocellular carcinoma in vivo. Mechanistically, it inhibited the phospho-signal transducer and activator of transcription-3 in a dose- and time-dependent manner. Furthermore, NT157 treatment suppressed the c-Jun activation domain-binding protein-1 levels in the nucleus but no significant decrease was observed in its expression in the cytoplasm. Finally, high mRNA expression levels of signal transducer and activator of transcription-3 and c-Jun activation domain-binding protein-1 in hepatocellular carcinoma were associated with significantly low survival rates. Conclusion: NT157 inhibits hepatocellular carcinoma migration and metastasis by downregulating the signal transducer and activator of transcription-3/c-Jun activation domain-binding protein-1 signaling pathway and targeting it may serve as a novel therapeutic strategy for the clinical management of hepatocellular carcinoma in the future.

Sign in / Sign up

Export Citation Format

Share Document